Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2026 | The future of AI in hematology: personalized medicine, opportunities and risks

Adrián Mosquera Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, discusses how artificial intelligence (AI) could transform hematology and oncology through integrated patient data analysis, personalized treatment selection, and earlier prediction of complications. He also highlights concerns around overreliance on AI in medical training, including the risk of reduced critical thinking and clinical skills among future physicians. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I think we are going to see a lot of computational tools analyzing integrated patient data. For example, in hematology, we’re going to see more and more integration of genomics, imaging, PET-CT or computer tomography imaging. Even digital health technologies, which monitor you over time, can be also plotted into an integrated system where AI can identify patterns and anticipate complications, etc...

I think we are going to see a lot of computational tools analyzing integrated patient data. For example, in hematology, we’re going to see more and more integration of genomics, imaging, PET-CT or computer tomography imaging. Even digital health technologies, which monitor you over time, can be also plotted into an integrated system where AI can identify patterns and anticipate complications, etc. I think that’s quite feasible and probably will lead to a more personalized and better and more anticipation in the complication management of many patients. It will obviously also help us deliver the adequate drugs, mitigate adverse birth events, drug interactions, etc. That’s the good part. I think we’ll also have many more drugs to test because this foundational model, some proteomics, is also being used to generate in-silico more small molecule inhibitors. And therefore, we’ll probably have more molecules to test in patients who need them. But still I see a big challenge with medical education and the risk of de-skilling or never-skilling that our fellows will suffer by being exposed too much to advanced AI use. This is probably one of the big issues. There is a huge concern. The data indicates that most young doctors use regulated AI tools, like ChatGPT, to manage their patients. And therefore, this will probably have an impact on their critical capacity to judge what AI is doing. And therefore, I see huge opportunities, but very relevant risks on the table that someone should start analyzing them and making actions to mitigate them.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.